News | May 04, 2026
Lilly posts explosive Q1 2026 results
Lifts full-year outlook as obesity drug boom accelerates
Lifts full-year outlook as obesity drug boom accelerates
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
